Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (244)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by HARDIE, R. J.
Right arrow Articles by STERN, G.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HARDIE, R. J.
Right arrow Articles by STERN, G.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 107, No. 2, 487-506, 1984
© 1984 Oxford University Press

research-article

ON-OFF FLUCTUATIONS IN PARKINSON'S DISEASE

A CLINICAL AND NEUROPHARMACOLOGICAL STUDY1

R. J. HARDIE, A. J. LEES and G.M. STERN

The Department of Neurology University College Hospital London WC1

On-off fluctuations have been studied in twenty patients with Parkinson's disease on long-term levodopa treatment. The pattern of fluctuations was related to the timing of oral levodopa ingestion in all patients. ‘Predictable’ fluctuators were characterized by fewer daily doses taken at longer intervals than ‘unpredictable’ fluctuators in whom individual dose responses tended to overlap. Most patients at least once a day experienced an unexplained failure of an oral dose to take effect.

Administration of levodopa by intravenous infusion at a constant rate brought about a dramatic extension in the duration of mobility and reduced the frequency of fluctuations compared with oral therapy; apomorphine consistently reversed off phases when administered shortly after their onset, whereas lisuride was less often effective.

We conclude that the development of a sustained-release formulation of levodopa would lead to improved control of the response fluctuations seen with conventional levodopa preparations.

.

Received June 28, 1983. Revised August 2, 1983.

1Preliminary results of this study were given at the Seventh International Symposium on Parkinson's Disease, at Frankfurt, June 1982.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 NeurologyHome page
W. Poewe
Treatments for Parkinson disease--past achievements and current clinical needs
Neurology, February 17, 2009; 72(7_Supplement_2): S65 - S73.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
R. de la Fuente-Fernandez, M. Schulzer, E. Mak, D. B. Calne, and A. J. Stoessl
Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model
Brain, April 1, 2004; 127(4): 888 - 899.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. A. LeWitt
Subcutaneously administered apomorphine: Pharmacokinetics and metabolism
Neurology, March 23, 2004; 62(6_suppl_4): S8 - S11.
[Abstract] [Full Text]

Home page
 NeurologyHome page
S. A. Factor
Literature review: Intermittent subcutaneous apomorphine therapy in Parkinson's disease
Neurology, March 23, 2004; 62(6_suppl_4): S12 - S17.
[Abstract] [Full Text]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A J Lees
Drugs for Parkinson's disease
J. Neurol. Neurosurg. Psychiatry, December 1, 2002; 73(6): 607 - 610.
[Full Text] [PDF]

Home page
 J. Neuropsychiatry Clin. Neurosi.Home page
B. A. Racette, J. M. Hartlein, T. Hershey, J. W. Mink, J. S. Perlmutter, and K. J. Black
Clinical Features and Comorbidity of Mood Fluctuations in Parkinson's Disease
J Neuropsychiatry Clin Neurosci, November 1, 2002; 14(4): 438 - 442.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
R. B. Dewey Jr, J. T. Hutton, P. A. LeWitt, and S. A. Factor
A Randomized, Double-blind, Placebo-Controlled Trial of Subcutaneously Injected Apomorphine for Parkinsonian Off-State Events
Arch Neurol, September 1, 2001; 58(9): 1385 - 1392.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
M Alegret, C Junque, F Valldeoriola, P Vendrell, M J Marti, and E Tolosa
Obsessive-compulsive symptoms in Parkinson's disease
J. Neurol. Neurosurg. Psychiatry, March 1, 2001; 70(3): 394 - 396.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
A. J. Manson, H. Hanagasi, K. Turner, P. N. Patsalos, P. Carey, N. Ratnaraj, and A. J. Lees
Intravenous apomorphine therapy in Parkinson's disease: Clinical and pharmacokinetic observations
Brain, February 1, 2001; 124(2): 331 - 340.
[Abstract] [Full Text] [PDF]

Home page
 J. Neuropsychiatry Clin. Neurosi.Home page
I. H. Richard, A. W. Justus, and R. Kurlan
Relationship Between Mood and Motor Fluctuations in Parkinson's Disease
J Neuropsychiatry Clin Neurosci, February 1, 2001; 13(1): 35 - 41.
[Abstract] [Full Text]

Home page
 J. Neurophysiol.Home page
K. J. Black, T. Hershey, M. H. Gado, and J. S. Perlmutter
Dopamine D1 Agonist Activates Temporal Lobe Structures in Primates
J Neurophysiol, July 1, 2000; 84(1): 549 - 557.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
P. Piccini, D. J Brooks, K. Korpela, N. Pavese, M. Karlsson, and A. Gordin
The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease
J. Neurol. Neurosurg. Psychiatry, May 1, 2000; 68(5): 589 - 594.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. J. Blanchet, S. Konitsiotis, and T. N. Chase
Motor Response to a Dopamine D3 Receptor Preferring Agonist Compared to Apomorphine in Levodopa-Primed 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Monkeys
J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 794 - 794.
[Abstract] [Full Text]

Home page
 Arch NeurolHome page
J. E. Ahlskog, M. D. Muenter, D. M. Maraganore, J. Y. Matsumoto, A. Lieberman, K. F. Wright, and K. Wheeler
Fluctuating Parkinson's Disease: Treatment With the Eong-Acting Dopamine Agonist Cabergoline
Arch Neurol, December 1, 1994; 51(12): 1236 - 1241.
[Abstract] [PDF]

Home page
 J Biomater ApplHome page
T. V. Chirila
Melanized Poly(HEMA) Hydrogels: Basic Research and Potential Use
J Biomater Appl, January 1, 1993; 8(2): 106 - 144.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
J. G. Nutt, W. R. Woodward, J. H. Carter, and S. T. Gancher
Effect of Long-term Therapy on the Pharmacodynamics of Levodopa: Relation to On-Off Phenomenon
Arch Neurol, November 1, 1992; 49(11): 1123 - 1130.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
B. T. H. Henderson, C. G. Clough, R. C. Hughes, E. R. Hitchcock, and B. G. Kenny
Implantation of Human Fetal Ventral Mesencephalon to the Right Caudate Nucleus in Advanced Parkinson's Disease
Arch Neurol, August 1, 1991; 48(8): 822 - 827.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
J. T. Hutton, J. L. Morris, G. C. Roman, S. C. Imke, and J. W. Elias
Treatment of Chronic Parkinson's Disease With Controlled-Release Carbidopa/Levodopa
Arch Neurol, August 1, 1988; 45(8): 861 - 864.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
J. T. Hutton, J. W. Albrecht, G. C. Roman, and M. T. Kopetzky
Prolonged Serum Levodopa Levels With Controlled-Release Carbidopa-Levodopa in the Treatment of Parkinson's Disease
Arch Neurol, January 1, 1988; 45(1): 55 - 57.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
J. L. Juncos, G. Fabbrini, M. M. Mouradian, and T. N. Chase
Controlled Release Levodopa-Carbidopa (CR-5) in the Management of Parkinsonian Motor Fluctuations
Arch Neurol, October 1, 1987; 44(10): 1010 - 1012.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.